Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12,

04/03/13		
	of entity ALX LIMITED	
ABN 59 009	9 575 035	
We (t	he entity) give ASX the followir	ng information.
	1 - All issues ust complete the relevant sections (atta	ch sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Performance Rights
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	12,000,000 Performance Rights.
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Performance Rights, which subject to the Company's Shares trading on ASX achieving a volume weighted average trading price of not less than \$0.09 for not less than 15 consecutive trading days on or before 12 December 2022, the Performance Rights will automatically be capable of conversion into Shares within 6 months.

Appendix 3B Page 1 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

No. Shares issued on vesting of Performance Do the \*securities rank equally 4 Rights will rank equally with the Company's Fully in all respects from the +issue Paid Ordinary Shares. date with an existing +class of auoted +securities? If the additional \*securities do not rank equally, please state: • the date from which they do the extent to which they participate for the next dividend, (in the case of a distribution) trust, interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Nil cash consideration. Issue price or consideration 5 Performance Rights issued to Directors as a long-Purpose of the issue 6 term incentive, as approved by shareholders on (If issued as consideration for 21 November 2019. the acquisition of assets, clearly identify those assets) Yes 6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 21 November 2019 6b The date the security holder resolution under rule 7.1A was passed Number of \*securities issued N/A 6c without security holder approval under rule 7.1 6d Number of \*securities issued N/A with security holder approval

under rule 7.1A

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)			
6f	Number of *securities issued under an exception in rule 7.2	12,000,000 Perfo	ormance Rights	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15-day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A		
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A		
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1: 80,020,754 7.1A: 59,621,678		
	1 .	10.5	010	
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	12 December 20	J19	
		Number	+Class	
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	605,628,549	Fully Paid Ordinary Shares	

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (*including* the \*securities in section 2 if applicable)

Number	+Class
6,172,840	Unlisted Options exercisable at \$0.0324 on or before 1 September 2020
6,107,755	Unlisted Options exercisable at \$0.0324 each on or before 8 September 2020
8,800,000	Unlisted Options exercisable at \$0.0324 each on or before 18 September 2020
2,000,000	Unlisted Options exercisable at \$0.22 each on or before 10 December 2023
3,000,000	Unlisted Options exercisable at \$0.25 each on or before 10 December 2023
4,000,000	Unlisted Options exercisable at \$0.30 each on or before 10 December 2023
2,768,382	Unlisted Options exercisable at \$0.0847 each on or before 17 May 2022
2,500,000	Unlisted Options exercisable at \$0.10 each on or before 30 June 2024
9,000,000	Performance Rights, subject to performance-based vesting conditions detailed in the Company's notice of meeting dated 3 October 2018, expiring 10 December 2023
7,500,000	Performance Rights which subject to the Company Shares trading on ASX achieving a volume weighted average trading price of not less than \$0.09 for not less than 15 consecutive trading days on or before 11 July 2022, the Performance Rights will automatically be capable of conversion into Shares within 6 months.
12,000,000	Performance Rights which subject to the Company Shares trading on ASX achieving a volume weighted average trading price of not

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

less than \$0.09 for not less than 15 consecutive trading days on or before 12 December 2022, the Performance Rights will automatically be capable of conversion into Shares within 6 months.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

The Company does not have a dividend policy

## Part 2 - Pro rata issue

11	Is security holder approval N/A required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities N/A will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
15	<sup>+</sup> Record date to determine N/A entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of N/A	

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B New issue announcement

	NI C 1	TNI/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee	N/A
	or commission	
22	Names of any brokers to the	N/A
	issue	
23	Fee or commission payable to	N/A
<del>-</del> 3	the broker to the issue	
24	Amount of any handling fee	N/A
	payable to brokers who lodge	
	acceptances or renunciations on	
	behalf of security holders	
2-	If the issue is contingent on	NI/A
25	If the issue is contingent on security holders' approval, the	N/A
	date of the meeting	
	Ö	
26	Date entitlement and acceptance	N/A
	form and offer documents will be	
	sent to persons entitled	
		[NI/A
27	If the entity has issued options, and the terms entitle option	N/A
	holders to participate on	
	exercise, the date on which	
	notices will be sent to option	
	holders	
		T
28	Date rights trading will begin (if	N/A
	applicable)	
29	Date rights trading will end (if	N/A
29	applicable)	
30	How do security holders sell	N/A
	their entitlements <i>in full</i> through a broker?	
	a DIONEL:	
31	How do security holders sell <i>part</i>	N/A
٠,	of their entitlements through a	, ·
	broker and accept for the	
	balance?	

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

32	of the	do security holders dispose eir entitlements (except by hrough a broker)?	N/A
33	<sup>+</sup> Issue	e date	N/A
You ne	ed only o		<b>S</b> oplying for quotation of securities
34	(tick	of *securities one)	
(a)		<sup>+</sup> Securities described in Part	1
(b)		All other *securities	
		•	nd of the escrowed period, partly paid securities that become fully paid en restriction ends, securities issued on expiry or conversion of convertible
Entiti	es tha	t have ticked box 34(a)	
Addi	tional	securities forming a new	v class of securities
Tick to docum		e you are providing the informat	ion or
35			securities, the names of the 20 largest holders of the he number and percentage of additional *securities
36			securities, a distribution schedule of the additiona umber of holders in the categories
		1,001 - 5,000 5,001 - 10,000	
		10,001 - 100,000 100,001 and over	
37		A copy of any trust deed for	the additional *securities
Entiti	es tha	t have ticked box 34(b)	
38		per of <sup>+</sup> securities for which ation is sought	

<sup>+</sup> See chapter 19 for defined terms.

39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the <sup>+</sup> securities in clause 38)		

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Jamon (sotso

Sign here: Date: 12 December 2019

(Company Secretary)

Print name: Shannon Coates

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

## Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	510,789,343	
Add the following:	36,321,122 shares issued 15 May 2019	
Number of fully paid <sup>+</sup> ordinary securities     is a set of the security paid and t	24,691,358 shares issued 1 July 2019	
issued in that 12-month period under an exception in rule 7.2	1,895,453 shares issued 13 May 2019	
Number of fully paid +ordinary securities	19,046,519 shares issued 17 May 2019	
issued in that 12-month period with shareholder approval	1,576,568 shares issued 27 May 2019	
<ul> <li>Number of partly paid +ordinary securities that became fully paid in that 12-month period</li> </ul>	1,896,422 shares issued 18 June 2019	
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12-month period	0	
"A"	596,216,785	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	89,432,518	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of +equity securities issued or agreed to be issued in that 12-month period not counting those issued:	9,411,764 shares issued 15 November 2019	
Under an exception in rule 7.2		
Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	9,411,764	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	89,432,518	
Note: number must be same as shown in Step 2		
Subtract "C"	9,411,764	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	80,020,754	
	[Note: this is the remaining placement capacity under rule 7.1]	

<sup>+</sup> See chapter 19 for defined terms.

## Part 2-

Rule 7.1A – Additional placem	nent capacity f	or eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated				
"A"		596,216,785		
Note: number must be same as shown in St	ep 1 of Part 1			
Step 2: Calculate 10% of "A"				
"D"		0.10		
		Note: this value cannot be changed		
Multiply "A" by 0.10		59,621,678		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used				
<ul> <li>Insert number of †equity securities issued or issued in that 12-month period under rule 7.2</li> <li>Notes:         <ul> <li>This applies to equity securities – not just securities</li> <li>Include here – if applicable – the securities of the Appendix 3B to which this form is at the point of the period of the equity securities issued under the equity securities issued under the equity helder approval has been obtained.</li> <li>It may be useful to set out issues of securities as separate line items</li> </ul> </li> </ul>	t ordinary es the subject ennexed nder rule 7.1 which specific	Nil		
"E"		Nil		
Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A				
"A" x 0.10	59,621,678			
Note: number must be same as shown in Step 2				
Subtract "E"	0			
Note: number must be same as shown in Step 3				
<i>Total</i> ["A" x 0.10] – "E"	59,621,678			
	Note: this is t	he remaining placement er rule 7.1A		

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 12 04/03/2013